Concepedia

Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells

Katie Maurer, Haesook T. Kim, Heather Garrity, Deborah Liney, Corey Cutler, Joseph H. Antin, John Koreth, Jerome Ritz, Roman M. Shapiro, Rizwan Romee,

Blood Advances · 2023 · 12 citations · 16 references

DOIFull text

Open access

Concepts

References

16

HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Leo Luznik, Paul V. O’Donnell, Heather J. Symons et al. · Biology of Blood and Marrow Transplantation · 2008 · 1.9K citations · Full text

, , +16

Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression

Lucas P. Wachsmuth, Michael T. Patterson, Michael Eckhaus et al. · Journal of Clinical Investigation · 2019 · 289 citations · Full text

, , +14

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

Javier Bolaños‐Meade, Ran Reshef, Raphael Fraser et al. · The Lancet Haematology · 2019 · 281 citations

, , +16

Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies

Journal of Clinical Oncology · 2021 · 168 citations · Full text

, , +17

Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide

Christopher G. Kanakry, David G. Coffey, Andrea Towlerton et al. · JCI Insight · 2016 · 146 citations · Full text

, , +17